Skip to main content

7 Result(s)

within Hideko Goto Remove this filter

and

  1. Article

    Open Access

    Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population

    We compared the predictive ability of the International Prognostic Index (IPI), a frequently used prognostic model for peripheral T-cell lymphoma (PTCL), with that of a type-specific prognostic model, the Prog...

    Nobuhiko Nakamura, Nobuhiro Kanemura, Takuro Matsumoto… in Scientific Reports (2023)

    Download PDF (1635 KB) View Article

  2. Article

    Spur cell anemia related to alcoholic liver cirrhosis managed without liver transplantation: a case report and literature review

    Spur cell anemia is an acquired hemolytic anemia associated with liver cirrhosis and is characterized by the presence of increased large red blood cells, which are covered with spike-like projections that vary...

    Takao Miwa, Yuichiro Hatano, Takahiro Kochi… in Clinical Journal of Gastroenterology (2020)

    Download PDF (1670 KB) View Article

  3. No Access

    Article

    Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens

    Serum concentration of soluble interleukin-2 receptor (sIL-2R) predicts the clinical outcome of patients with aggressive non-Hodgkin's lymphoma treated with the cyclophosphamide, doxorubicin, vincristine, and ...

    Naoe Goto, Hisashi Tsurumi, Hideko Goto, Yoriko Ino Shimomura… in Annals of Hematology (2012)

  4. No Access

    Article

    Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma

    We previously described the effectiveness of the THP-COP regimen comprising cyclophosphamide, pirarubicin (tetrahydropyranyl adriamycin; THP), vincristine and prednisolone in patients with diffuse large B-cell...

    Takeshi Hara, Hisashi Tsurumi, Naoe Goto… in Journal of Cancer Research and Clinical On… (2010)

  5. No Access

    Article

    Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP

    We previously reported that serum concentrations of soluble Fas (sFas) predict the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) after treatment with CHOP but without rituximab (R). H...

    Takeshi Hara, Hisashi Tsurumi, Naoe Goto… in Journal of Cancer Research and Clinical On… (2009)

  6. No Access

    Article

    Late-Onset Neutropenia in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma

    Late-onset grade 4 neutropenia occurred in 3 (5.6%) of 54 non-Hodgkin’s lymphoma patients treated with rituximab between September 2001 and March 2004. Neutropenia appeared 5 to 25 weeks after administration o...

    Kenji Fukuno, Hisashi Tsurumi, Nobuhiro Ando… in International Journal of Hematology (2006)

  7. No Access

    Article

    Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index

    The aim of the present study was to assess the prognostic significance of serum soluble interleukin-2 receptor (sIL-2R) in aggressive non-Hodgkin’s lymphoma (NHL).

    Hideko Goto, Hisashi Tsurumi, Masao Takemura… in Journal of Cancer Research and Clinical On… (2005)